612 related articles for article (PubMed ID: 26273492)
1. A Comprehensive Overview of Skeletal Phenotypes Associated with Alterations in Wnt/β-catenin Signaling in Humans and Mice.
Maupin KA; Droscha CJ; Williams BO
Bone Res; 2013 Mar; 1(1):27-71. PubMed ID: 26273492
[TBL] [Abstract][Full Text] [Related]
2. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
[TBL] [Abstract][Full Text] [Related]
3. LRP5, Bone Mass Polymorphisms and Skeletal Disorders.
Littman J; Yang W; Olansen J; Phornphutkul C; Aaron RK
Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895195
[TBL] [Abstract][Full Text] [Related]
4. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.
Levasseur R; Lacombe D; de Vernejoul MC
Joint Bone Spine; 2005 May; 72(3):207-14. PubMed ID: 15850991
[TBL] [Abstract][Full Text] [Related]
5. Clinical features, treatment, and follow-up of OPPG and high-bone-mass disorders: LRP5 is a key regulator of bone mass.
Ren N; Lv S; Li X; Shao C; Wang Z; Mei Y; Yang W; Fu W; Hu Y; Sha L; Hu W; Zhang Z; Wang C
Osteoporos Int; 2024 Apr; ():. PubMed ID: 38625381
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass.
Ferrari SL; Deutsch S; Antonarakis SE
Curr Opin Lipidol; 2005 Apr; 16(2):207-14. PubMed ID: 15767861
[TBL] [Abstract][Full Text] [Related]
7. New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.
Whyte MP; McAlister WH; Zhang F; Bijanki VN; Nenninger A; Gottesman GS; Lin EL; Huskey M; Duan S; Dahir K; Mumm S
Bone; 2019 Oct; 127():228-243. PubMed ID: 31085352
[TBL] [Abstract][Full Text] [Related]
8. Exploiting the WNT Signaling Pathway for Clinical Purposes.
Johnson ML; Recker RR
Curr Osteoporos Rep; 2017 Jun; 15(3):153-161. PubMed ID: 28432596
[TBL] [Abstract][Full Text] [Related]
9. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome.
Ai M; Heeger S; Bartels CF; Schelling DK;
Am J Hum Genet; 2005 Nov; 77(5):741-53. PubMed ID: 16252235
[TBL] [Abstract][Full Text] [Related]
10. [Wnt-beta-catenin signaling in bone metabolism].
Urano T
Clin Calcium; 2006 Jan; 16(1):54-60. PubMed ID: 16397351
[TBL] [Abstract][Full Text] [Related]
11. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop.
Rawadi G; Vayssière B; Dunn F; Baron R; Roman-Roman S
J Bone Miner Res; 2003 Oct; 18(10):1842-53. PubMed ID: 14584895
[TBL] [Abstract][Full Text] [Related]
12. Treatment and management of osteoporosis-pseudoglioma syndrome.
Levasseur R
Expert Rev Endocrinol Metab; 2008 May; 3(3):337-348. PubMed ID: 30754200
[TBL] [Abstract][Full Text] [Related]
13. High-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypes.
Niziolek PJ; Farmer TL; Cui Y; Turner CH; Warman ML; Robling AG
Bone; 2011 Nov; 49(5):1010-9. PubMed ID: 21855668
[TBL] [Abstract][Full Text] [Related]
14. Lrp5 Mutant and Crispant Zebrafish Faithfully Model Human Osteoporosis, Establishing the Zebrafish as a Platform for CRISPR-Based Functional Screening of Osteoporosis Candidate Genes.
Bek JW; Shochat C; De Clercq A; De Saffel H; Boel A; Metz J; Rodenburg F; Karasik D; Willaert A; Coucke PJ
J Bone Miner Res; 2021 Sep; 36(9):1749-1764. PubMed ID: 33957005
[TBL] [Abstract][Full Text] [Related]
15. New Insights into Wnt-Lrp5/6-β-Catenin Signaling in Mechanotransduction.
Kang KS; Robling AG
Front Endocrinol (Lausanne); 2014; 5():246. PubMed ID: 25653639
[TBL] [Abstract][Full Text] [Related]
16. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.
Gong Y; Slee RB; Fukai N; Rawadi G; Roman-Roman S; Reginato AM; Wang H; Cundy T; Glorieux FH; Lev D; Zacharin M; Oexle K; Marcelino J; Suwairi W; Heeger S; Sabatakos G; Apte S; Adkins WN; Allgrove J; Arslan-Kirchner M; Batch JA; Beighton P; Black GC; Boles RG; Boon LM; Borrone C; Brunner HG; Carle GF; Dallapiccola B; De Paepe A; Floege B; Halfhide ML; Hall B; Hennekam RC; Hirose T; Jans A; Jüppner H; Kim CA; Keppler-Noreuil K; Kohlschuetter A; LaCombe D; Lambert M; Lemyre E; Letteboer T; Peltonen L; Ramesar RS; Romanengo M; Somer H; Steichen-Gersdorf E; Steinmann B; Sullivan B; Superti-Furga A; Swoboda W; van den Boogaard MJ; Van Hul W; Vikkula M; Votruba M; Zabel B; Garcia T; Baron R; Olsen BR; Warman ML;
Cell; 2001 Nov; 107(4):513-23. PubMed ID: 11719191
[TBL] [Abstract][Full Text] [Related]
17. The role of the Wnt signaling pathway in osteoblast commitment and differentiation.
Yavropoulou MP; Yovos JG
Hormones (Athens); 2007; 6(4):279-94. PubMed ID: 18055419
[TBL] [Abstract][Full Text] [Related]
18. Heterozygosity for an inactivating mutation in low-density lipoprotein-related receptor 6 (Lrp6) increases osteoarthritis severity in mice after ligament and meniscus injury.
Joiner DM; Less KD; Van Wieren EM; Hess D; Williams BO
Osteoarthritis Cartilage; 2013 Oct; 21(10):1576-85. PubMed ID: 23756208
[TBL] [Abstract][Full Text] [Related]
19. [Wnt signaling molecules related to osteoporosis].
Kubota T; Ozono K
Clin Calcium; 2013 Jun; 23(6):855-60. PubMed ID: 23719498
[TBL] [Abstract][Full Text] [Related]
20. Wnt signaling: a key regulator of bone mass.
Baron R; Rawadi G; Roman-Roman S
Curr Top Dev Biol; 2006; 76():103-27. PubMed ID: 17118265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
